# Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors

> **NCT01343498** · PHASE1 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 33 (actual)

## Conditions studied

- Malignant Solid Tumour

## Interventions

- **DRUG:** BEZ235

## Key facts

- **NCT ID:** NCT01343498
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2015-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01343498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01343498, "Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01343498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*